Autoimmune Diseases
Navigator Medicines Launches with $100 Million Series A Funding to Advance Autoimmune Disease Bispecific Antibody
Navigator Medicines, autoimmune disease, bispecific antibody, Series A funding, RA Capital Management, Forbion
Bicara and Zenas File for IPOs to Advance Late-Phase Cancer and Autoimmune Treatments
Bicara Therapeutics, Zenas BioPharma, IPO, cancer treatment, autoimmune disease, biotech, pharmaceuticals
Caribou Biosciences Discontinues CAR-NK Program, Lays Off 21 Employees to Focus on CAR-T Cell Therapies
Caribou Biosciences, CAR-NK, CAR-T, cell therapy, layoffs, biotech, cancer treatment, autoimmune diseases
Artiva Biotherapeutics Seeks $116M in Second IPO Attempt for Cell Therapy Development
Artiva Biotherapeutics, IPO, cell therapy, AlloNK, systemic lupus erythematosus, autoimmune diseases
SciRhom Secures €63 Million in Series A Funding for Autoimmune Therapies
SciRhom, autoimmune diseases, iRhom2, therapeutic strategy, Series A funding, biotech, pharmaceuticals
Cartesian Therapeutics Announces Positive Phase 2b Results for Descartes-08 in Myasthenia Gravis Treatment
Cartesian Therapeutics, Descartes-08, Myasthenia Gravis, Phase 2b Trial, CAR-T Therapy, Autoimmune Disorder
Argenx’s Vyvgart Hytrulo Secures Second US Approval for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Vyvgart Hytrulo, Argenx, FDA Approval, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Autoimmune Disease, Peripheral Nervous System Disorder
Kyverna’s CAR-T Relapse in Lupus Dents Autoimmune Hopes Amid Biotech Gold Rush
Kyverna, CAR-T, Lupus, Autoimmune Disease, Biotech, Gold Rush, Relapse, Clinical Trials, Gene Therapy
J&J’s Nipocalimab Shows Promise in Sjögren’s Disease with Significant Phase 2 Results
nipocalimab, Sjögren’s disease, Johnson & Johnson, Phase 2 study, autoimmune disease, FcRn inhibitor
Amgen’s Uplizna Achieves Phase 3 Success in Treating Immunoglobulin G4-Related Disease, Paving Way for Label Expansion
Amgen, Uplizna, Phase 3, Immunoglobulin G4-Related Disease, IgG4-RD, Rare Autoimmune Disease, Label Expansion